Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer

BACKGROUND: Despite broad advances in multimodal treatment of locally advanced breast cancer (LABC), 30 to 40% of patients develop loco-regional relapse. The aim of this study was to analyze in a retrospective manner the effectiveness of concurrent chemo-radiotherapy (CCRTh) after neoadjuvant chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarado-Miranda, Alberto, Arrieta, Oscar, Gamboa-Vignolle, Carlos, Saavedra-Perez, David, Morales-Barrera, Rafael, Bargallo-Rocha, Enrique, Zinser-Sierra, Juan, Perez-Sanchez, Victor, Ramirez-Ugalde, Teresa, Lara-Medina, Fernando
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716349/
https://www.ncbi.nlm.nih.gov/pubmed/19591689
http://dx.doi.org/10.1186/1748-717X-4-24
Descripción
Sumario:BACKGROUND: Despite broad advances in multimodal treatment of locally advanced breast cancer (LABC), 30 to 40% of patients develop loco-regional relapse. The aim of this study was to analyze in a retrospective manner the effectiveness of concurrent chemo-radiotherapy (CCRTh) after neoadjuvant chemotherapy (NCT) in patients with LABC. METHODS: One hundred twelve patients with LABC (stage IIB-IIIB) were treated with NCT (5-fluorouracil 500 mg/m(2), doxorubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2 )(FAC), or doxorubicin 50 mg/m(2 )and cyclophosphamide 500 mg/m(2 )(AC) IV in four 21-day courses) followed by CCRTh (60 Gy breast irradiation and weekly mitomycin 5 mg/m(2), 5-fluorouracil 500 mg/m(2), and dexamethasone 16 mg, or cisplatin 30 mg/m(2), gemcitabine 100 mg/m(2 )and dexamethasone 16 mg), and 6–8 weeks later, surgery and two additional courses of FAC, AC, or paclitaxel 90 mg/m(2 )weekly for 12 weeks, and in case of estrogen-receptor positive patients, hormonal therapy. RESULTS: Stages IIB, IIIA and -B were 21.4, 42.9, and 35.7%, respectively. Pathological complete response (pCR) in the breast was 42% (95% CI, 33.2–50.5%) and, 29.5% (95% CI, 21.4–37.5%) if including both the breast and the axillary nodes. Multivariate analysis showed that the main determinant of pCR was negative estrogen-receptor status (HR = 3.8; 95% CI, 1.5–9; p = 0.016). The 5-year disease-free survival (DFS) was 76.9% (95% CI, 68.2–84.7%). No relationship between pCR and DFS was found. Multivariate analysis demonstrated that the main DFS determinant was clinical stage (IIB and IIIA vs. IIIB, HR = 3.1; 95% CI, 1.02–9.74; p = 0.04). Only one patient had local recurrence. Five-year overall survival was 84.2% (95% CI, 75–93.2%). The toxicity profile was acceptable. CONCLUSION: This non-conventional multimodal treatment has good loco-regional control for LABC. Randomized clinical trials of preoperative CCRTh following chemotherapy, in patients with LABC are warranted.

Ejemplares similares